Berberine-mediated STAT3 inhibition reduced IL-10 expression in melanoma cells; reprogrammed M2 tumor-associated macrophages to a tumorsuppressive M1 phenotype; increased tumor cell recognition by T cells; and ultimately reduced tumor burden in melanoma-bearing mice (128). Here, STAT3 is linked to neoplasm.